Last reviewed · How we verify
SYS6010
SYS6010 is a small molecule targeting the PD-1/PD-L1 pathway.
SYS6010 is a small molecule targeting the PD-1/PD-L1 pathway. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | SYS6010 |
|---|---|
| Sponsor | Fujian Cancer Hospital |
| Drug class | PD-1/PD-L1 inhibitor |
| Target | PD-1/PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
SYS6010 works by inhibiting the PD-1/PD-L1 interaction, which is a key checkpoint in the immune system. This allows the immune system to recognize and attack cancer cells more effectively.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Pneumonitis
- Fatigue
- Diarrhea
Key clinical trials
- A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors (PHASE1)
- SYS6090 Combination Therapy in Advanced Lung Cancer (PHASE1, PHASE2)
- SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ (PHASE3)
- SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma (PHASE3)
- A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer (PHASE3)
- A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC (PHASE3)
- SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (PHASE2)
- A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SYS6010 CI brief — competitive landscape report
- SYS6010 updates RSS · CI watch RSS
- Fujian Cancer Hospital portfolio CI